×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Organization: Denali Therapeutics
organization
1,453 words
KG: therapeutics
2026-03-29
kind:organization
section:organizations
type:biotech
focus:parkinsons
focus:lrkk2
focus:trem2
stage:clinical
country:usa
Contents
Denali Therapeutics
Knowledge Graph
Related Hypotheses (30)
Blood-Brain Barrier SPM Shuttle System
Score: 0.55
TREM2-mediated microglial tau clearance enhancement
Score: 0.49
Complement C1QA Spatial Gradient in Cortical Layers
Score: 0.43
TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegen
Score: 0.64
TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegene
Score: 0.61
Smartphone-Detected Motor Variability Correction
Score: 0.56
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.41
Glymphatic-Mediated Tau Clearance Dysfunction
Score: 0.55
Dual-Circuit Tau Vulnerability Cascade
Score: 0.50
Dopaminergic Ventral Tegmental-Hippocampal Circuit Protectio
Score: 0.49
SASP-Mediated Complement Cascade Amplification
Score: 0.70
Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95
Score: 0.69
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
CYP46A1 Overexpression Gene Therapy
Score: 0.63
Prime Editing Precision Correction of APOE4 to APOE3 in Micr
Score: 0.62
APOE-Dependent Autophagy Restoration
Score: 0.61
Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbate
Score: 0.61
Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Multi-Modal Stress Response Harmonization
Score: 0.60
Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.59
Microbial Inflammasome Priming Prevention
Score: 0.58
PARP1 Inhibition Therapy
Score: 0.58
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.57
Show 25 more
Related Analyses (29)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Show 24 more
Related Experiments (30)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Longitudinal TLR2 reporter gene study in α-synuclein mice
validation · proposed · Score: 0.90
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
Dexamethasone treatment study in α-synuclein mice
validation · proposed · Score: 0.85
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
TLR expression in α-synuclein overexpressing mice
validation · proposed · Score: 0.80
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne
validation · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.40
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.40
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · proposed · Score: 0.90
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Trehalose-induced lysosomal changes and TFEB activation
exploratory · proposed · Score: 0.90
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
Trehalose-induced lysosomal membrane permeabilization and TF
exploratory · proposed · Score: 0.90
Functional validation of trehalose effects on misfolded prot
exploratory · proposed · Score: 0.85
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
Biomarker-Guided Sequential Therapy Selection in Alzheimer's
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Lifestyle Intervention Mechanisms in Alzheimer's Disease
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
VCP Proteostasis Modulation Therapy for ALS/FTD
idea · KG edge: references
CX3CR1 Modulation Therapy for Neurodegeneration
idea · KG edge: references
NLRP3 Inflammasome Hypothesis in Parkinson's Disease
hypothesis · KG edge: references
APOE contributes to Alzheimer's disease by regulating b
hypothesis · KG edge: references
SIRT6 Gene
gene · KG edge: references
PPARGC1A Gene
gene · KG edge: references
NURR1 Gene
gene · KG edge: references
C3 — Complement Component 3
gene · KG edge: references
BDNF Gene
gene · KG edge: references
TREM2 Protein (Triggering Receptor Expressed on Myeloid
entity · KG edge: references
TLR4 (Redirect)
redirect · KG edge: references
TFEB (Redirect)
redirect · KG edge: references
GFAP (Redirect)
redirect · KG edge: references
BACE1 (Redirect)
redirect · KG edge: references
Neuroinflammation PET Imaging in CBS/PSP
diagnostic · KG edge: inhibits
Show 10 more
Knowledge Graph (2 edges)
therapeutics
protects_against
age-related cognitive decline
therapeutics
inhibits
neuroinflammation